FDA Panel: Reformulated OxyContin Did Not Reduce Overall Abuse

Sponsored By admin
Oct 23, 2020, 6:54 AM

An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma’s abuse-deterrent formulation (ADF) of oxycodone (OxyContin) “meaningfully reduced” overall opioid abuse, overdose, and death.

Show Your Support

Access the report

Read the full report

Want to keep reading? Subscribers get exclusive access to DHI's extensive library of content, covering top-of-mind issues and trends for today's healthcare executive.

Featured Insights